A previous meta-analysis indicated that PD-1 inhibitors and combination immunotherapy demonstrate promising clinical responses and overall survival (OS) rates, alongside manageable adverse events (AEs) in the treatment of dMMR colorectal cancer (60). Here, PDCD1 is linked to colorectal cancer.